Let me tell you, folks, we’ve got something huge here. We’re talking about a game-changer in the world of prostate cancer. You know, they used to say, if you’ve got pelvic nodal metastases, that’s it, you’re at stage IV. But we’ve got new tech on the block, the PSMA PET, and it’s doing things differently, doing things better.

So, we did this study, a big study, to see if men diagnosed with this PSMA PET thing have better outcomes than the old way. And guess what? The results, they’re incredible, absolutely incredible. We looked at 76 men, all with the cancer just in the pelvis. Fifty-one were spotted by this fantastic PSMA PET, and the other 25, the old way. And the differences, folks, they’re night and day.

The guys checked with PSMA PET? They had less severe disease, lower PSA levels, I mean, 11 ng/mL compared to 26 ng/mL. That’s not winning, that’s dominating. And survival, let’s talk about survival. After 4 years, 72% of the PSMA PET group were doing great, compared to just 38% of the old-school group. And overall survival? 93% for PSMA PET, 76% for the others. We’re not just winning; we’re changing the game.

And when we crunched the numbers, really crunched them, the PSMA PET group had a threefold improvement in survival without biochemical failure. That’s not luck, that’s skill. And overall survival? Nearly six times better. The numbers, they don’t lie.

So, what we’re saying here, what we’re proving, is that men with PSMA PET-detected node-positive prostate cancer, they’re not just surviving; they’re thriving. Better control, better survival. It’s clear, it’s proven. PSMA PET, it’s the future, and it’s a bright one.